Cryptotanshinone Suppressed Postmenopausal Osteoporosis by Preventing RANKL-Mediated Osteoclastogenesis Against Kidney Injury
January 2022
in “
Evidence-based Complementary and Alternative Medicine
”
TLDR Cryptotanshinone may help treat postmenopausal osteoporosis and protect kidneys.
The study investigated the effects of Cryptotanshinone (CPT) on postmenopausal osteoporosis using a rat model of OVX-induced osteoporosis. It found that CPT significantly improved bone mineral density and content, reduced bone loss, and enhanced collagen formation, indicating its potential to ameliorate osteoporosis. Additionally, CPT protected against kidney damage by reducing glomerular atrophy and normalizing creatinine levels. In vitro studies showed that CPT decreased the expression of osteoclast-specific proteins, suggesting its efficacy in inhibiting osteoclastogenesis. CPT exhibited no toxicity at doses below 10 µM, highlighting its safety as a treatment option for osteoporosis.
